NovoCure Limited Ordinary Shares (NVCR)
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
- Headquarters
- United States
- Employees
- 1,605
- Market Cap
- $1.8B
About NovoCure Limited Ordinary Shares
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
SentiSense also tracks daily options readings for NovoCure Limited Ordinary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
NovoCure Limited Ordinary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.